您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > PR-924
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PR-924
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PR-924图片
CAS NO:1416709-79-9
包装与价格:
包装价格(元)
100 mg电议
500 mg电议

产品介绍

产品描述

PR-924 is a selective inhibitor of tripeptide epoxyketone immunoproteasome subunit LMP-7 (IC50: 22 nM). PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities. PR-924 covalently modifies proteasomal N-terminal threonine active sites.

体外活性

PR-924 causes BID cleavage and its translocation to mitochondria, as well as cyto-c release BID, a proapoptotic BH-3 family protein, is linked to mitochondrial-mediated apoptotic signaling pathways via cyto-c release. PR-924 (3 μM; 48 hours; MM.1S and MM.1R cells) treatment triggers apoptosis in MM cells. PR-924 (3 μM; 48 hours; MM.1S and MM.1R cells) treatment triggers activation of caspase-3, caspase-8, and caspase-9, and significantly down-regulated the expression of Bcl-2 protein, without altering Bax or MCL-1 protein levels. PR-924 (1-20 μM; 24-72 hours; MM.1S, MM.1R, RPMI-8226, KMS12, LR-5, DOX40, INA-6, OPM1, and OPM2 cells) treatment obviously reduces the viability of all the MM cell lines in a time-and dose-dependent manner (IC 50 range for cell lines: 3-7 μM for 48 h)[1].

体内活性

PR-924 treatment obviously decreases the shIL-6R levels in SCID-hu model. Treatment of tumor-bearing mice with PR-924 prolongs survival. PR-924 (6 mg/kg; intravenous injection; twice a week; for 21 days; CB-17 SCID-mice) treatment obviously inhibits tumor growth in human plasmacytoma xenografts [1].

Cas No.

1416709-79-9

分子式

C37H38N4O5

分子量

618.72

储存和溶解度

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years